Fonseca Biosciences Drug Patent Portfolio
Fonseca Biosciences owns 1 orange book drug protected by 6 US patents Given below is the list of Fonseca Biosciences's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9504691 | Finafloxacin suspension compositions | 21 Nov, 2033 | Active |
| US8536167 | Methods for treating ophthalmic, otic, or nasal infections | 08 Aug, 2031 | Active |
| US9119859 | Methods for treating otic infections | 02 Jul, 2030 | Active |
| US9993483 | Compositions and methods for treating ophthalmic, octic, or nasal infections | 02 Jul, 2030 | Active |
| US6133260 | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | 12 Apr, 2017 | Expired |
| US6432948 | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases | 12 Apr, 2017 | Expired |
Latest Legal Activities on Fonseca Biosciences's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Fonseca Biosciences.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 06 May, 2024 | US9504691 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 21 Feb, 2023 | US9119859 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 23 Nov, 2022 | US9993483 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Nov, 2022 | US9119859 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Nov, 2022 | US9504691 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Nov, 2022 | US8536167 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US9119859 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US9993483 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US8536167 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US9504691 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Dec, 2021 | US9993483 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 30 Sep, 2020 | US8536167 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Jul, 2020 | US9119859 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Jul, 2020 | US9993483 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Jul, 2020 | US8536167 |
Fonseca Biosciences's Family Patents
Fonseca Biosciences drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 21.4% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Fonseca Biosciences Drug List
Given below is the complete list of Fonseca Biosciences's drugs and the patents protecting them.
1. Xtoro
Xtoro is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9504691 | Finafloxacin suspension compositions |
21 Nov, 2033
(9 years from now)
| Active |
| US8536167 | Methods for treating ophthalmic, otic, or nasal infections |
08 Aug, 2031
(6 years from now)
| Active |
| US9119859 | Methods for treating otic infections |
02 Jul, 2030
(5 years from now)
| Active |
| US9993483 | Compositions and methods for treating ophthalmic, octic, or nasal infections |
02 Jul, 2030
(5 years from now)
| Active |
| US6133260 | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases |
12 Apr, 2017
(7 years ago)
| Expired |
| US6432948 | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases |
12 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xtoro's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List